Cystic Fibrosis Foundation Therapeutics Inc. announced an award of up to $5M to Editas Medicine Inc. to advance potential gene editing approaches for cystic fibrosis.
Site Search
The Cystic Fibrosis Foundation has awarded more than $23 million across 11 sites in its Research Development Program (RDP), a network of research centers that brings together top-notch scientists from different disciplines to apply their expertise to the challenges of treating cystic fibrosis.
On Oct. 4, the Warren Alpert Foundation honored five CF scientists, including Dr. Francis Collins, for their trailblazing work in CF research. The Foundation received special acknowledgement for our role in driving this progress, marking the first time that an organization has been recognized by the Alpert Foundation.
The studies aim to improve our understanding of a common cause of lung transplant failures, a condition known as chronic lung allograft dysfunction (CLAD).
Icagen Inc. will focus on drug discovery, screening for compounds that could suppress nonsense mutations, and using computer modeling to identify molecules that are suitable to be developed into drugs.
The Cystic Fibrosis Foundation has launched a new program that will fund 60 additional research coordinators to help speed the progress of CF clinical trials throughout its Therapeutics Development Network (TDN).
The Cystic Fibrosis Foundation recently hosted the CFF Research Conference: Pushing the Frontiers, bringing together nearly 150 basic scientists, clinical researchers, graduate students and pharmaceutical company representatives to share information on recent advances and critical challenges in CF drug discovery and development.
The Cystic Fibrosis Foundation today announced an unprecedented acceleration and expansion of its research, care and patient programs for the CF community. This action is possible as a result of the sale of the Foundation's royalty rights to CF treatments developed by Vertex Pharmaceuticals Inc. The Foundation received $3.3 billion from the sale to Royalty Pharma.
The physical footprint of the Cystic Fibrosis Foundation Therapeutics Lab grew by about a third this year, enabling startup companies and industry scientists to work and learn alongside lab staff.